scispace - formally typeset
O

Otto C. Boerman

Researcher at Radboud University Nijmegen

Publications -  358
Citations -  17532

Otto C. Boerman is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Radioimmunotherapy & In vivo. The author has an hindex of 66, co-authored 355 publications receiving 15882 citations. Previous affiliations of Otto C. Boerman include Radboud University Nijmegen Medical Centre.

Papers
More filters
Journal ArticleDOI

Functionalization of multilayered DNA-coatings with bone morphogenetic protein 2

TL;DR: The results demonstrate the feasibility of multilayered DNA-coatings to be functionalized by embedding BMP-2 according to three different loading modalities: superficial (s), deep (d), and double-layer (dl).
Journal ArticleDOI

PET Radioimmunoscintigraphy of Renal Cell Cancer Using 89Zr-Labeled cG250 Monoclonal Antibody in Nude Rats

TL;DR: Scintigraphic tumor imaging using chimeric moAb G250 labeled with 89Zr (immuno-PET) or 111In (RIS), and [18F]FDG-(PET) was explored in rats with s.c. renal cell carcinoma (RCC) tumors, and relatively small tumors could be visualized, even without a dedicated PET camera for small animals.
Journal ArticleDOI

Caffeine Prevents Protection in Two Human Models of Ischemic Preconditioning

TL;DR: Caffeine abolishes IP in 2 human models at a dose equivalent to the drinking of 2 to 4 cups of coffee, and in vitro, IP improved post-ischemic functional recovery in the control group, but not in the caffeine group.
Journal Article

Absolute organ activity estimated by five different methods of background correction.

TL;DR: Even though quantitative SPECT is the most rigorous method for activity quantification in conditions of low organ-to-background activity concentration ratio, planar scintigraphy can be applied accurately if appropriate attention is paid to background correction.
Journal ArticleDOI

Radio-labeled receptor-binding peptides: A new class of radiopharmaceuticals

TL;DR: Radio-labeled receptor-binding peptides have emerged as an important class of radiopharmaceuticals, and peptides binding to these receptors can be used to visualize tumor lesions scintigraphically and for peptide-receptor radionuclide therapy.